A rapid and sensitive High-Performance Liquid Chromatography method with fluorescence detection for quantification of melatonin in small volume rat plasma samples

application to a preclinical study to determine the oral pharmacokinetics of melatonin under gestational conditions

Authors

DOI:

https://doi.org/10.1590/

Keywords:

Melatonin, High-Performance Liquid Chromatography, Pharmacokinetics, Gestation, Rats

Abstract

A novel, simple and sensitive high-performance liquid chromatography with fluorescence detection method was developed and validated for the characterization of the preclinical pharmacokinetics of melatonin under pregnant conditions. Plasma samples (25 µL) were treated with 30 µL of ethanol absolute (containing the internal standard, IS). After a centrifugation process, aliquots of supernant (5 µL) were injected into the chromatographic system. Compounds were eluted on a Xbridge C18 (150 mm x 4.6 mm i.d., 5 µm particle size) maintained at 30°C. The mobile phase consisted in a mixture of aqueous solution of 0.4% phosphoric acid and acetonitrile (70:30 v/v). The wavelengths were set at 305 nm (excitation) and 408 nm (emission) and the total analysis time was 8 min/sample. All validation tests were obtained with accuracy and precision, according to FDA guidelines, over the concentration range of 0.005-20 µg/mL. Pharmacokinetic study showed that melatonin systemic exposure increased from day 14, with a significant difference at 19 days of gestation compared to the control group. Our findings suggest a decreased metabolism of melatonin as result of temporary physiological changes that occur throughout pregnancy. However, other maternal physiological changes cannot be ruled out.

Downloads

Download data is not yet available.

References

Andersen LP, Werner MU, Rosenkilde MM, Harpsøe NG, Fuglsang H, Rosenberg J, et al. Pharmacokinetics of oral and intravenous melatonin in healthy volunteers. BMC Pharmacol Toxicol. 2016;17. https://doi:10.1186/s40360-016-0052-2

» https://doi:10.1186/s40360-016-0052-2

Anderson J, Reiter R. Melatonin: roles in influenza, Covid-19, and other viral infections. Rev Med Virol. 2020;30(3). https:/doi.org/10.1002/rmv.2109

» https:/doi.org/10.1002/rmv.2109

Anderson G, Carr D. Effect of pregnancy on the pharmacokinetics of antihypertensive drugs. Clin Pharmacokinet. 2009;48(3):159-168. https://doi.org/10.2165/00003088-200948030-00002

» https://doi.org/10.2165/00003088-200948030-00002

Arreola-Espino R, Urquiza-Marín H, Ambriz-Tututi M, Araiza-Saldaña CI, Caram-Salas NL, Rocha-González HI, et al. Melatonin reduces formalin-induced nociception and tactile allodynia in diabetic rats. Eur J Pharmacol. 2007;577(1-3):203-10.

Carloni S, Proietti F, Rocchi M, Longini M, Marseglia L, D’Angelo G, et al. Melatonin pharmacokinetics following oral administration in preterm neonates. Molecules. 2017;22(12). https://doi.org/10.3390/molecules22122115

» https://doi.org/10.3390/molecules22122115

Chen M, Stone R. Lack of effect of oral melatonin on platelet parameters in normal healthy dogs. J Am Anim Hosp Assoc. 2019;55(5):226-30.

Cheung RT, Tipoe GL, Tam S, Ma ES, Zou LY, Chan PS. Preclinical evaluation of pharmacokinetics and safety of melatonin in propylene glycol for intravenous administration. J Pineal Res. 2006;41(4):337-43.

Choudhary S, Kumar A, Saha N, Choudhary N. PK-PD based optimal dose and time for orally administered supra-pharmacological dose of melatonin to prevent radiation induced mortality in mice. Life Sci. 2019;219:31-9.

Coppola P, Kerwash E, Nooney J, Omran A, Cole S. Pharmacokinetic data in pregnancy: A review of available literature data and important considerations in collecting clinical data. Front Med. 2022;9. https://doi:10.3389/fmed.2022.940644

» https://doi:10.3389/fmed.2022.940644

Di WL, Kadva A, Johnston A, Silman R. Variable bioavailability of oral melatonin. N Engl J Med. 1997;336(14):1028-29.

Feghali M, Venkataramanan R, Caritis S. Pharmacokinetics of drugs in pregnancy. Semin Perinatol. 2015;39(7):512-19.

Gaohua L, Abduljalil K, Jamei M, Johnson TN, Rostami-Hodjegan A. A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4. Br J Clin Pharmacol. 2012;74(5):873-85.

Harpsøe NG, Andersen LP, Gögenur I, Rosenberg J. Clinical pharmacokinetics of melatonin: a systematic review. Eur J Clin Pharmacol. 2015;71(8):901-9.

Härtter S, Grözinger M, Weigmann H, Röschke J, Hiemke C. Increased bioavailability of oral melatonin after fluvoxamine coadministration. Clin Pharmacol Ther. 2000;67(1):1-6.

Härtter S, Ursing C, Morita S, Tybring G, von Bahr C, Christensen M, et al. Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: a pilot study. Clin Pharmacol Ther . 2001;70(1):10-6.

Härtter S, Nordmark A, Rose DM, Bertilsson L, Tybring G, Laine K. Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity. Br J Clin Pharmacol . 2003;56(6):679-82.

Hemati K, Pourhanifeh MH, Dehdashtian E, Fatemi I, Mehrzadi S, Reiter RJ, et al. Melatonin and morphine: potential beneficial effects of co-use. Fundam Clin Pharmacol. 2021;35(1):25-39.

Hendawy A, El-Toukhey N, AbdEl-Rahman S, Ahmed H. Ameliorating effect of melatonin against nicotine induced lung and heart toxicity in rats. Environ Sci Pollut Res Int. 2021;28(27):35628-41.

Ke A, Rostami-Hodjegan A, Zhao P, Unadkat J. Pharmacometrics in pregnancy: An unmet need. Annu Rev Pharmacol Toxicol. 2014;54:53-69.

Ma X, Idle JR, Krausz KW, Gonzalez FJ. Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos. 2005;33(4),489-94.

Mexican Official Norm NOM-062-ZOO-1999. Especificaciones técnicas para la producción, cuidado y uso de los animales de laboratorio (2001). Official Journal of the Federation. Mexico City, Mexico. https://www.gob.mx/cms/uploads/attachment/file/203498/NOM-062-ZOO-1999_220801.pdf

» https://www.gob.mx/cms/uploads/attachment/file/203498/NOM-062-ZOO-1999_220801.pdf

Mexican Official Norm (2013) NOM-177-SSA1-2013. Que establece las pruebas y procedimientos para demostrar que un medicamento es intercambiable. Requisitos a que deben sujetarse los Terceros Autorizados que realicen las pruebas de intercambiabilidad (2013). Requirement 9.1. Official Journal of the Federation, Mexico City, Mexico. https://www.dof.gob.mx/nota_detalle.php?codigo=5314833&fecha=20/09/2013#gsc.tab=0

» https://www.dof.gob.mx/nota_detalle.php?codigo=5314833&fecha=20/09/2013#gsc.tab=0

Miguel FM, Picada JN, da Silva JB, Schemitt EG, Colares JR, Hartmann RM, et al. Melatonin attenuates inflammation, oxidative stress, and DNA damage in mice with nonalcoholic steatohepatitis induced by a methionine- and choline-deficient diet. Inflammation. 2022;45(5):1968-84.

Moroni I, Garcia-Bennett A, Chapman J, Grunstein RR, Gordon CJ, Comas M. Pharmacokinetics of exogenous melatonin in relation to formulation, and effects on sleep: A systematic review. Sleep Med Rev. 2021;57. https://doi.org/10.1016/j.smrv.2021.101431

» https://doi.org/10.1016/j.smrv.2021.101431

NC3Rs (National Centre for the Replacement, Refinement & Reduction of Animal Research of United Kingdom). Available at: Available at: https://www.nc3rs.org.uk/ (Accessed on December 2020)

» https://www.nc3rs.org.uk/

Nickkholgh A, Schneider H, Sobirey M, Venetz WP, Hinz U, Pelzl LH, et al. The use of high-dose melatonin in liver resection is safe: first clinical experience. J Pineal Res . 2011;50(4):381-88.

Roy J, Wong KY, Aquili L, Uddin MS, Heng BC, Tipoe GL, et al. Role of melatonin in Alzheimer’s disease: from preclinical studies to novel melatonin-based therapies. Front Neuroendocrinol. 2022;65. https://doi.org/10.1016/j.yfrne.2022.100986

» https://doi.org/10.1016/j.yfrne.2022.100986

Shah VP, Midha KK, Findlay JW, Hill HM, Hulse JD, McGilveray IJ, et al. Bioanalytical method validation--a revisit with a decade of progress. Pharm Res. 2000;17(12):1551-7.

Shuster D, Bammler T, Beyer R, Macdonald J, Tsai J, Farin F, et al. Gestational age-dependent changes in gene expression of metabolic enzymes and transporters in pregnant mice. Drug Metab Dispos . 2013;41(2):332-42.

Srinivas N. Should commonly prescribed drugs be avoided as internal standard choices in new assays for clinical samples? Bioanalysis. 2016;8(7):607-10.

Tamura H, Nakamura Y, Terrón MP, Flores LJ, Manchester LC, Tan DX, et al. Melatonin and pregnancy in the human. Reprod Toxicol. 2008;25(3):291-303.

Tracy T, Venkataramanan R, Glover D, Caritis S, National Institute for Child Health and Human Development Network of Maternal-Fetal-Medicine Unit. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A activity) during pregnancy. Am J Obstet Gynecol. 2005;192(2):633-9.

U.S. Department of Health and Human Services - Food and Drug Administration - Center for Drug Evaluation and Research (CDER) - Center for Veterinary Medicine (CVM). 2018. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioanalytical-methodvalidation-guidance-industry (Accessed on December 2020).

» https://www.fda.gov/regulatory-information/search-fda-guidance-documents/bioanalytical-methodvalidation-guidance-industry

Vine T, Brown G, Frey B. Melatonin use during pregnancy and lactation: a scoping review of human studies. Braz J Psychiatry. 2022;44(3):342-8.

Walker A, Dickmann L, Isoherranen N. Pregnancy decreases rat CYP1A2 activity and expression. Drug Metab Dispos . 2011;39(1):4-7.

Wetterberg L. Melatonin and clinical application. Reprod Nutr Dev. 1999;39(3):367-82.

Xu S, Wei W, Shen Y, Hao J, Ding C. Studies on the antiinflammatory, immunoregulatory, and analgesic actions of melatonin. Drug Dev Res. 1996;39(2):167-73.

Yeleswaram K, McLaughlin L, Knipe J, Schabdach D. Pharmacokinetics and oral bioavailability of exogenous melatonin in preclinical animal models and clinical implications. J Pineal Res . 1997;22(1):45-51.

Yu T, Campbell SC, Stockman C, Tak C, Schoen K, Clark E, et al. Pregnancy-induced changes in the pharmacokinetics of caffeine and its metabolites. J Clin Pharmacol. 2016;56(5):590-6.

Zhao H, Wang Y, Yuan B, Liu S, Man S, Xu H, et al. A novel LC-MS/MS assay for the simultaneous determination of melatonin and its two major metabolites, 6-hydroxymelatonin and 6-sulfatoxymelatonin in dog plasma: application to a pharmacokinetic study. J Pharm Biomed Anal. 2016;117:390-7.

Zisapel N. New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation. Br J Pharmacol. 2018;175(16):3190-9.

Downloads

Published

2024-11-05

Issue

Section

Article

How to Cite

A rapid and sensitive High-Performance Liquid Chromatography method with fluorescence detection for quantification of melatonin in small volume rat plasma samples: application to a preclinical study to determine the oral pharmacokinetics of melatonin under gestational conditions. (2024). Brazilian Journal of Pharmaceutical Sciences, 60. https://doi.org/10.1590/